{"id":"csa-eye-gel","safety":{"commonSideEffects":[{"rate":"10%","effect":"Eye irritation"},{"rate":"5%","effect":"Blurred vision"},{"rate":"3%","effect":"Eye pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CsA works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes.","oneSentence":"Calcineurin inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:09:21.597Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Keratitis"},{"name":"Uveitis"}]},"trialDetails":[{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06766357","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease","status":"RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-04-03","conditions":"Moderate to Severe Dry Eye","enrollment":360},{"nctId":"NCT06942793","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Treatment With CsA-PG Ophthalmic Gel in Dry Eye Patients","status":"NOT_YET_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-05-20","conditions":"Dry Eye Disease","enrollment":396},{"nctId":"NCT06392438","phase":"PHASE3","title":"Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users","status":"RECRUITING","sponsor":"Université de Sherbrooke","startDate":"2024-04-25","conditions":"Dry Eye, Contact Lens Complication","enrollment":44},{"nctId":"NCT04541888","phase":"PHASE3","title":"Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2020-11-05","conditions":"Dry Eye","enrollment":644},{"nctId":"NCT03287635","phase":"PHASE4","title":"Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Toyos Clinic","startDate":"2018-07-01","conditions":"Dry Eye Disease","enrollment":19},{"nctId":"NCT03676335","phase":"PHASE2","title":"Assess the Safety and Efficacy of CsA Ophthalmic Gel in Subjects With Dry Eye","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2018-05-09","conditions":"Dry Eye","enrollment":240},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT02028312","phase":"PHASE4","title":"A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®","status":"WITHDRAWN","sponsor":"Edward Holland, MD","startDate":"2014-01","conditions":"Dry Eye Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CsA gel"],"phase":"phase_2","status":"active","brandName":"CsA eye gel","genericName":"CsA eye gel","companyName":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","companyId":"zhaoke-guangzhou-ophthalmology-pharmaceutical-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Calcineurin inhibitor Used for Keratitis, Uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}